Synergistic Multitherapy as a Rational Strategy in Aging: Multifactorial Process

Riga, Sorin; Riga, Dan

doi:10.1111/j.1749-6632.1998.tb09926.x

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AS homeostatic‐regenerative antistress/antiaging actions have been confirmed by multiple, comparative, independent, and the present authors' research in preclinical animal studies3 and also in multicenter clinical human trials4,5 in stress medicine, as well as in mental, behavioral, and senescence disorders:6,7 (1) neurotic and stress‐related disorders: F43 reaction to severe stress and adjustment disorders (F43.1, F43.2) and F48 other neurotic disorders (F48.0); (2) mood (affective) disorders: F32 depressive episode (F32.0, F32.1, F32.2) and F33 recurrent depressive disorder (F33.0, F33.1, F33.3); (3) behavioral syndromes associated with physiological disturbances and physical factors: F52 sexual dysfunction, not caused by organic disorder or disease (F52.0, F52.1, F52.2, F52.3, F52.5, F52.6); (4) mental and behavioral disorders due to psychoactive substance use: F10‐alcohol, F13‐sedatives or hypnotics, F15‐other stimulants, including caffeine, F17‐tobacco/nicotine; (5) organic, including symptomatic, mental disorders (OMD): F00 dementia in Alzheimer disease (F00.1), F01 vascular dementia (F01.1), F04 organic amnesic syndrome not induced by alcohol/other psychoactive substances, F06 other OMD due to brain damage and dysfunction and to physical disease (F06.32, F06.4, F06.6, F06.7).…”

Section: Resultssupporting

confidence: 63%

Prolongevity Medicine: Antagonic‐Stress® Drug in Distress, Geriatrics, and Related Diseases. II. Clinical Review—2003

Riga

Schneider

2004

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Distress and senescence, their reciprocal aggravating-quickening connections, and their related pathologies have a large worldwide impact on healthcare systems in this new millennium. For this reason, Antagonic-Stress (AS)--an advanced integrative therapy, with specific synergistic composition, and patented internationally--represents a significant strategy in health, aging, and longevity. Clinical research with AS proves the drug's efficacy in the management of distress (neurotic, stress-related, and affective disorders; behavioral syndromes associated with physiological disturbances and physical factors; mental and behavioral disorders due to psychoactive substance uses) and psychogeriatrics [organic, including symptomatic, mental disorders (OMD)]. Specific multiaxial psychopathological instruments and psychometric tests in multiple assessments used for gerontopsychiatry demonstrated strong improvements after AS administration in early-moderate stages of Alzheimer or vascular dementia, as well as in other OMD. In addition, comparative clinical studies evinced the superiority of AS (synergistic multitherapy) versus monotherapy [meclofenoxate (MF), piracetam (PA), pyritinol (PT), and nicergoline (NE), respectively]. These comparative clinical trials agreed closely with comparative preclinical research and confirmed AS synergistic homeostatic, adaptogenic, antioxidative, cerebrovascular, neurometabolic, and nootropic actions. Also, the AS protective actions against oxidative stress recommend this orthomolecular therapy in stress, aging, and free radical pathology.

show abstract

Section: Resultssupporting

confidence: 63%